<DOC>
	<DOCNO>NCT00473265</DOCNO>
	<brief_summary>Whereas much information know property bone primary hyperparathyroidism , disorder parathyroid hormone ( PTH ) excess , virtually nothing know skeleton hypoparathyroidism , disorder PTH absent . The purpose research project test hypothesis skeleton hypoparathyroidism abnormal metabolic , densitometric , geometric , biomechanical microarchitectural feature . We also test hypothesis skeleton dependent upon PTH normal structure function . Using non-invasive approach well direct analysis bone , human hypoparathyroid skeleton thoroughly characterize . With patient serve his/her control , determine , extent , way administration PTH restore skeletal dynamic structure hypoparathyroid skeleton . In way , identify structural dynamic element skeleton influence dependent upon PTH . Methods utilized include dual energy X-ray absorptiometry , quantitative central peripheral compute tomography , geometry size quantification , histomorphometry standard microCT method , finite element analysis , biochemical bone marker , quantitative back scattered electron imaging , Fourier Transform Infrared Spectroscopy . This research project extend knowledge skeletal effect PTH deficient range thus complete understand PTH action bone gain many year study PTH overexpression primary hyperparathyroidism . This investigation may also provide insight mean PTH help restore skeleton use treat osteoporosis .</brief_summary>
	<brief_title>Bone Properties Hypoparathyroidism : Effects PTH</brief_title>
	<detailed_description>A detailed description method use study include follow : direct analysis bone . skeletal dynamic structure dual energy X-ray absorptiometry , quantitative central peripheral compute tomography , geometry size quantification , histomorphometry standard microCT method , finite element analysis , biochemical bone marker , quantitative back scattered electron imaging , Fourier Transform Infrared Spectroscopy .</detailed_description>
	<mesh_term>Hypoparathyroidism</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Hypoparathyroidism Bisphosphonate use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>